The introduction of the Tandem Mass Spectrometry (MS/MS) in neonatal screening laboratories has opened the way to innovative newborn screening analysis.
With this technology the number of metabolic disorders that can be detected from dried blood-spot species increases significantly.
However, the amount of information obtained with this technique and the pressure for quick and accurate diagnostics raises serious difficulties in the daily data analysis.
To face this challenge, we developed a software system, NeoScreen, which simplifies and allow speeding up newborn screening diagnostics.
NeoScreen is a complete platform for decision support in newborn screening programs based on MS/MS technology, allowing the detection of abnormalities related to metabolic diseases. It is a fully web platform and it has been used in different regions, countries and continents. We support TSH and T4 biomarkers for Congenital Hypothyroidism and much more.
